Jason Tardio

Executive Officer at Immunic

Capital raised by Immunic

$200.0M+$200.0M latest round

1 Form D filing · first filed Feb 2026 · New York, NY

CURRENT ROLE: Executive Officer
SECTOR: Biotech
COMPANY FILINGS: 1
TEAM ON FILE: 2
FOUNDED: —
30D INTEREST: 2 ↗

Career

1 company on file

ImmunicBiotech · New York, NYsince Feb 2026

Executive Officer

Listed on Immunic's Form D filings

Company filings

via EDGAR · Form D for Immunic1

DateCompanyFormAmountRole on filing

Feb 17, 2026ImmunicForm D+$200.0M—

Form DFeb 17, 2026 · Immunic+$200.0Mnot a signer

Overview

Last filing Feb 17, 2026

Jason Tardio is on file as Executive Officer at Immunic in New York, NY. Immunic has 1 Form D filing on record, $200.0M raised in total.

Teammates

Immunic · 1

Daniel VittChief Executive OfficerSigner

Products

Immunic · 1

Vidofludimus calcium (IMU-838)Oral Neurologic Therapy

Vidofludimus calcium is the company's lead oral drug candidate, currently in Phase 3 (ENSURE-1 and ENSURE-2) clinical trials for the treatment of relapsing multiple sclerosis (RMS). It has also demonstrated positive activity in Phase 2 trials for progressive MS and ulcerative colitis. The company plans to initiate a Phase 3 trial for primary progressive multiple sclerosis (PPMS) in 2026.